找回密码
 To register

QQ登录

只需一步,快速开始

扫一扫,访问微社区

Titlebook: Novel Therapeutics for Rare Lymphomas; Christopher Dittus Book 2020 Springer Nature Switzerland AG 2020 lymphoma.novel therapeutics for ra

[复制链接]
查看: 54839|回复: 55
发表于 2025-3-21 16:50:19 | 显示全部楼层 |阅读模式
书目名称Novel Therapeutics for Rare Lymphomas
编辑Christopher Dittus
视频videohttp://file.papertrans.cn/669/668467/668467.mp4
概述Discusses the clinical presentation, diagnosis, and treatment approach to rare lymphomas.Focuses on new diagnostic approaches, novel chemotherapy combinations, and new treatment modalities with novel
图书封面Titlebook: Novel Therapeutics for Rare Lymphomas;  Christopher Dittus Book 2020 Springer Nature Switzerland AG 2020 lymphoma.novel therapeutics for ra
描述.This comprehensive volume reviews the clinical presentation, diagnosis, and treatment approach to rare lymphomas. There is particular emphasis placed on new diagnostic approaches, novel chemotherapy combinations, and treatment modalities with novel therapeutics. It highlights research advances in a group of diseases that are often overlooked, and serves as a single repository of information on the most recent advances in targeted small molecule inhibitors, monoclonal antibodies, immunotherapy, and CAR-T therapy as they pertain to rare types of lymphoma. Written for practicing oncologists, hematologists, fellows, and residents, .Novel Therapeutics for Rare Lymphomas. covers rare subtypes of lymphoma, including indolent and aggressive T-cell lymphomas and B-cell lymphomas..
出版日期Book 2020
关键词lymphoma; novel therapeutics for rare lymphomas; rare lymphomas; novel therapeutics; t-cell lymphomas; ag
版次1
doihttps://doi.org/10.1007/978-3-030-25610-4
isbn_softcover978-3-030-25612-8
isbn_ebook978-3-030-25610-4
copyrightSpringer Nature Switzerland AG 2020
The information of publication is updating

书目名称Novel Therapeutics for Rare Lymphomas影响因子(影响力)




书目名称Novel Therapeutics for Rare Lymphomas影响因子(影响力)学科排名




书目名称Novel Therapeutics for Rare Lymphomas网络公开度




书目名称Novel Therapeutics for Rare Lymphomas网络公开度学科排名




书目名称Novel Therapeutics for Rare Lymphomas被引频次




书目名称Novel Therapeutics for Rare Lymphomas被引频次学科排名




书目名称Novel Therapeutics for Rare Lymphomas年度引用




书目名称Novel Therapeutics for Rare Lymphomas年度引用学科排名




书目名称Novel Therapeutics for Rare Lymphomas读者反馈




书目名称Novel Therapeutics for Rare Lymphomas读者反馈学科排名




单选投票, 共有 0 人参与投票
 

0票 0%

Perfect with Aesthetics

 

0票 0%

Better Implies Difficulty

 

0票 0%

Good and Satisfactory

 

0票 0%

Adverse Performance

 

0票 0%

Disdainful Garbage

您所在的用户组没有投票权限
发表于 2025-3-21 23:17:35 | 显示全部楼层
发表于 2025-3-22 00:27:03 | 显示全部楼层
Immunotherapy in Hodgkin Lymphoma and Other CD30+ Lymphomas,e Ki-1 antibody binding to Reed-Sternberg cells in Hodgkin lymphoma (Stein et al., Blood 66(4):848–858, 1985). Since it has high expression within Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL), variable expression in other non-Hodgkin lymphoma subgroups, and limited expression in n
发表于 2025-3-22 05:26:29 | 显示全部楼层
发表于 2025-3-22 12:40:50 | 显示全部楼层
发表于 2025-3-22 15:01:10 | 显示全部楼层
发表于 2025-3-22 19:32:55 | 显示全部楼层
发表于 2025-3-23 00:40:29 | 显示全部楼层
Novel Agents in Primary Central Nervous System Lymphoma,te-based therapies has improved patient outcomes in the first-line setting, the prognosis of relapsed and refractory disease is poor. PCNSL has a unique pathophysiology and gene expression profile, making it more amenable to novel targeted and immunotherapeutic agents. Therapies such as ibrutinib, n
发表于 2025-3-23 05:16:09 | 显示全部楼层
发表于 2025-3-23 09:04:24 | 显示全部楼层
Extranodal NK/T-Cell Lymphoma,and is characterized by localized lesions involving the nose, nasopharynx, or oropharynx. Extra-nasal disease is less common and generally more aggressive. The immunophenotype of ENKTCL is unique, with most cases expressing NK-cell markers (CD2+, cytoplasmic CD3+, and CD56+). Treatment options for l
 关于派博传思  派博传思旗下网站  友情链接
派博传思介绍 公司地理位置 论文服务流程 影响因子官网 吾爱论文网 大讲堂 北京大学 Oxford Uni. Harvard Uni.
发展历史沿革 期刊点评 投稿经验总结 SCIENCEGARD IMPACTFACTOR 派博系数 清华大学 Yale Uni. Stanford Uni.
QQ|Archiver|手机版|小黑屋| 派博传思国际 ( 京公网安备110108008328) GMT+8, 2025-8-22 14:55
Copyright © 2001-2015 派博传思   京公网安备110108008328 版权所有 All rights reserved
快速回复 返回顶部 返回列表